Analyst report. Big take out is that "the company plans a NASDAQ dual listing in 2023"
- Forums
- ASX - By Stock
- RAD
- Ann: RAD201 HER2 nanobody demonstrates favourable tumor targeting
Ann: RAD201 HER2 nanobody demonstrates favourable tumor targeting, page-5
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAD (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.01M |
Open | High | Low | Value | Volume |
3.6¢ | 3.6¢ | 3.5¢ | $28.90K | 825.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 427410 | 3.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.5¢ | 9204 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 427410 | 0.034 |
5 | 551815 | 0.033 |
4 | 445187 | 0.032 |
2 | 590000 | 0.031 |
6 | 268927 | 0.030 |
Price($) | Vol. | No. |
---|---|---|
0.035 | 9204 | 1 |
0.038 | 463157 | 2 |
0.039 | 425000 | 2 |
0.040 | 260704 | 4 |
0.041 | 385166 | 3 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
RAD (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online